Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.82 - $1.44 $52,828 - $92,772
-64,425 Reduced 62.26%
39,048 $40,000
Q1 2024

May 15, 2024

BUY
$1.17 - $1.94 $91,084 - $151,029
77,850 Added 303.83%
103,473 $151,000
Q4 2023

Feb 14, 2024

BUY
$1.02 - $1.47 $26,135 - $37,665
25,623 New
25,623 $33,000
Q1 2023

May 15, 2023

SELL
$1.63 - $2.02 $18,673 - $23,141
-11,456 Reduced 37.62%
18,997 $36,000
Q4 2022

Feb 14, 2023

BUY
$1.68 - $3.7 $28,726 - $63,266
17,099 Added 128.04%
30,453 $56,000
Q3 2022

Nov 14, 2022

SELL
$3.43 - $4.01 $20,281 - $23,711
-5,913 Reduced 30.69%
13,354 $49,000
Q2 2022

Aug 15, 2022

SELL
$1.76 - $3.82 $11,883 - $25,792
-6,752 Reduced 25.95%
19,267 $70,000
Q1 2022

May 16, 2022

BUY
$1.77 - $2.93 $14,496 - $23,996
8,190 Added 45.94%
26,019 $64,000
Q3 2021

Nov 15, 2021

BUY
$2.35 - $3.16 $41,898 - $56,339
17,829 New
17,829 $53,000
Q3 2020

Nov 16, 2020

SELL
$3.69 - $7.09 $284,868 - $547,348
-77,200 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$3.58 - $7.44 $97,787 - $203,223
-27,315 Reduced 26.14%
77,200 $574,000
Q1 2020

May 15, 2020

SELL
$3.49 - $9.2 $55,452 - $146,178
-15,889 Reduced 13.2%
104,515 $469,000
Q4 2019

Feb 14, 2020

BUY
$6.27 - $11.41 $4,301 - $7,827
686 Added 0.57%
120,404 $1.11 Million
Q3 2019

Nov 14, 2019

BUY
$4.75 - $8.38 $320,625 - $565,650
67,500 Added 129.27%
119,718 $838,000
Q2 2019

Aug 14, 2019

SELL
$6.4 - $10.94 $70,496 - $120,504
-11,015 Reduced 17.42%
52,218 $370,000
Q1 2019

May 15, 2019

SELL
$6.1 - $10.3 $27,108 - $45,773
-4,444 Reduced 6.57%
63,233 $0
Q4 2018

Feb 14, 2019

SELL
$5.84 - $11.92 $177,781 - $362,868
-30,442 Reduced 31.03%
67,677 $419,000
Q3 2018

Nov 13, 2018

BUY
$12.43 - $29.76 $1.22 Million - $2.92 Million
98,119 New
98,119 $0

Others Institutions Holding OPTN

About OptiNose, Inc.


  • Ticker OPTN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 83,277,504
  • Market Cap $42.5M
  • Description
  • OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...
More about OPTN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.